Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models
Ayesha Alvero, MD, MSc, professor, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.
Novel Immunomodulatory virus CARG-2020 for Recurrent ovarian cancer
At the 2023 Society of Gynecological Oncology’s Annual Meeting on Women’s Cancer in Tampa, Florida, Ayesha Alvero, MD, C.S. Mott Center at Wayne State University, Detroit, Michigan, discusses the use of the novel immunomodulatory virus CARG-2020 to restore immunosurveillance and establish anti-tumoral immunological memory to prevent ovarian cancer recurrence.
CaroGen’s CARG-2020 Preclinical Data on Ovarian Cancer Immunotherapy to be Presented Orally at the Society of Gynecologic Oncology Annual Meeting
Farmington, CT, November 8, 2022 – CaroGen Corporation (https://carogencorp.com), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that new preclinical data about the mechanism of action of CaroGen’s novel ovarian cancer immunotherapy, CARG-2020,
CaroGen Management to Speak at The World Vaccine & Immunotherapy Congress
Farmington, CT, September 5, 2022– CaroGen Corporation (https://carogencorp.com), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that Bijan Almassian, PhD, President & CEO,
Bijan Almassian, PhD. on LinkedIn: CaroGen in pact with NIH to develop flu vaccine – BioCT | 21 comments
We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine.
“Relational Contract” Supports Outsourcing Of Hepatitis B Immunotherapy
Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide chronically infected with hepatitis B virus (HBV). Currently there is no cure for HBV.
CaroGen and Wayne State University scientists report significant progress on development of CARG-2020 for the potential treatment of ovarian cancer
Farmington, Conn., Oct. 25, 2020 – Privately-held CaroGen Corp., in collaboration with a team of scientists at the C.S. Mott Center for Human Growth and Development at Wayne State University..
UConn Health, CaroGen Collaborate on Promising Technology for Colorectal Cancer Treatment
UConn Health researchers, along with industry partners, have developed a promising potential candidate for treating colorectal cancer.
Hepatitis B “Functional Cure” On The Way? A CDMO Helps Out
Great to have an interview with Louis Garguilo, Chief Editor, Outsourced Pharma regarding to one of our lead products, CARG-201 for potential functional cure of patients chronically infected with HBV.
2021 Tech 25: CaroGen targets breakthrough immunotherapy drug
Very honored to be selected by Hartford Business Journal as one of top 25 technology companies in state of Connecticut. We develop breakthrough immunotherapies and vaccines for cancer and infectious diseases.
Bijan Almassian : Striving To Build Super Vaccines and Immunotherapies – Global Business Leaders Mag
Bijan Almassian : Striving To Build Super Vaccines and Immunotherapies While the coronavirus has caused havoc throughout the globe. Another such disease that has haunted humanity for years is cancer. Throughout the years, many cancer researchers have…
CaroGen Corporation: Improving Health around the Globe by Developing Transformative Vaccines and Immunotherapy
It is humbling to be recognized by Healthcare Insight magazine as 10 most advanced biotech startups of 2021.